PharmD Info

A forum for Indian Pharmacy Professionals

Drug Regulatory Affairs - CMC Regulatory, Global regulatory, Medical Devices, Pharmaceutical Regulatory Details PPT and Guidelines and etc.
Forum rules: General rules are applicable for this forum- Find Here
  • User avatar
#2481
This guidance is intended to assist applicants preparing to submit to FDA abbreviated new drug applications (ANDAs). This guidance highlights common, recurring deficiencies that may lead to a delay in the approval of an ANDA. It also makes recommendations to applicants on how to avoid these deficiencies with the goal of minimizing the number of review cycles necessary for approval.

Guideline includes following details:
- PATENT AND EXCLUSIVITY DEFICIENCIES
- LABELING DEFICIENCIES
- PRODUCT QUALITY DEFICIENCIES
- BIOEQUIVALENCE DEFICIENCIES

To download the guidelines follow the below link.
Attachments:
(249.56 KiB) Downloaded 323 times
Scientific Writing as a Student

Entering scientific writing during your 2nd year o[…]

After being bitten by a snake, the function of a t[…]

PharmD Info - Highlights